Holen Sie sich die Stockscreener-App
21.97
3.22%
-0.73
Handel nachbörslich:
21.97
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Here’s what analysts think about Arcus Biosciences (RCUS) - MSN
WINTON GROUP Ltd Purchases Shares of 92,229 Arcus Biosciences, Inc. $RCUS - MarketBeat
Why Arcus Biosciences (RCUS) Is Up 9.5% After New Casdatifan Data And Pipeline Expansion - simplywall.st
Arcus Biosciences (RCUS) Valuation After Casdatifan Kidney Cancer Data Pipeline Update And Earnings - Sahm
How (RCUS) Movements Inform Risk Allocation Models - Stock Traders Daily
New Arcus Biosciences hires receive stock options at $23.43 - Stock Titan
Arcus Biosciences at Leerink Conference: Casdatifan’s Promising Data By Investing.com - Investing.com Canada
RCUS News Today | Why did Arcus Biosciences stock go down today? - MarketBeat
Is Arcus Biosciences Inc still a buy after recent gainsWeekly Trading Summary & Comprehensive Market Scan Insights - baoquankhu1.vn
Performance Recap: Can Arcus Biosciences Inc disrupt its industryJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - baoquankhu1.vn
Vanguard Group Inc. Increases Stock Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
Aug Sectors: Is Arcus Biosciences Inc in a long term uptrendQuarterly Performance Summary & Free High Return Stock Watch Alerts - baoquankhu1.vn
Citigroup Raises Arcus Biosciences (RCUS) Price Target to $45 | - GuruFocus
Citigroup Raises Arcus Biosciences (NYSE:RCUS) Price Target to $45.00 - MarketBeat
Fisher Asset Management LLC Acquires 640,990 Shares of Arcus Biosciences, Inc. $RCUS - MarketBeat
RCUS SEC FilingsArcus Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Arcus (RCUS) Q4 2025 Earnings Call Transcript - AOL.com
RCUS Stock Jumps 17.5% Despite $353M Net Loss: What $34 Fair Value Signals - TIKR.com
Arcus Biosciences (RCUS) Is Up 27.0% After Casdatifan Kidney Cancer Data And TKI-Free Strategy Shift - simplywall.st
The Analyst Verdict: Arcus Biosciences In The Eyes Of 5 Experts - Sahm
Arcus Biosciences: Q4 Beat And Casdatifan’s Story So Far (NYSE:RCUS) - Seeking Alpha
RCUS Analyst Rating Updated by Leerink Partners | RCUS Stock New - GuruFocus
Arcus Biosciences (NYSE:RCUS) Stock Price Expected to Rise, Leerink Partners Analyst Says - MarketBeat
Arcus Biosciences (NYSE:RCUS) Shares Up 9.5%Here's What Happened - MarketBeat
Arcus Biosciences (NYSE:RCUS) Given "Buy" Rating at HC Wainwright - MarketBeat
Arcus Biosciences Puts Casdatifan Kidney Cancer Data At Center Stage - Yahoo Finance
Arcus Biosciences (RCUS) Analyst Rating Reaffirmed with Target P - GuruFocus
HC Wainwright Brokers Increase Earnings Estimates for RCUS - MarketBeat
Performance Recap: Is Arcus Biosciences Inc stock a buy or sellEarnings Miss & Community Consensus Trade Alerts - baoquankhu1.vn
Can Arcus Biosciences Inc stock double in the next year2025 Growth vs Value & Accurate Technical Buy Alerts - baoquankhu1.vn
Assessing Arcus Biosciences (RCUS) Valuation After Recent Share Price Rebound And Casdatifan Expectations - simplywall.st
Arcus Biosciences Q4 Earnings Call Highlights - Yahoo Finance
Arcus Biosciences (RCUS) Posts US$106 Million Q4 Loss Reinforcing Bearish Profitability Narratives - Sahm
Arcus Biosciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NYSE:RCUS) 2026-02-27 - Seeking Alpha
Arcus Biosciences (RCUS) Stock Analysis: Is A 65% Upside In Reach? - DirectorsTalk Interviews
MRGPRX2 antagonists disclosed in Arcus Biosciences patent - BioWorld MedTech
FY2030 Earnings Estimate for RCUS Issued By HC Wainwright - MarketBeat
Cancer and immune drug developer Arcus Biosciences offers March webcast - Stock Titan
Is Arcus Biosciences (RCUS) Pricing Reflect Its 1‑Year Surge And Mixed Valuation Signals - simplywall.st
Arcus Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Arcus Biosciences earnings beat by $0.21, revenue fell short of estimates - Investing.com Canada
Arcus Biosciences Inc (RCUS) Q4 2025 Earnings Call Highlights: S - GuruFocus
Decoding Arcus Biosciences Inc (RCUS): A Strategic SWOT Insight - GuruFocus
Arcus Biosciences Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Arcus Biosciences beats EPS expectations in Q4 2025 - Investing.com Nigeria
RCUS: Casdatifan delivers superior efficacy in RCC, driving strong financials and market potential - TradingView
Arcus Biosciences Files For Mixed Shelf - TradingView
Arcus Biosciences (NYSE:RCUS) Issues Quarterly Earnings Results - MarketBeat
Arcus Biosciences : Reports Fourth-Quarter and Full-Year 2025 Financial Results an... - marketscreener.com
RCUS: 2025 net loss widened to $353M on $247M revenue; $1.0B cash supports late-stage pipeline - TradingView
Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q4 Revenue $33.0M, vs. FactSet Est of $35.7M - marketscreener.com
Arcus Biosciences, Inc. SEC 10-K Report - TradingView
Arcus Biosciences Earnings Review: Q4 Summary - Benzinga
Arcus Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Arcus Biosciences (RCUS) maps oncology and inflammation pipeline with partners - Stock Titan
Arcus Biosciences (RCUS) details 2025 loss and $1.0B cash runway - Stock Titan
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update - marketscreener.com
Arcus Biosciences Provides Pipeline Update on Its Clinical-Stage Investigational Molecules and Discovery Programs - marketscreener.com
Arcus Biosciences in spotlight: Kidney drug trial results at stake - Investing.com South Africa
Arcus Biosciences in spotlight: Kidney drug trial results at stake By Investing.com - Investing.com Nigeria
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):